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Background and aims: Behçet syndrome is a systemic inflammatory condition characterized by muco-cutaneous
and ocularmanifestations, with central nervous system, vascular and/or gastro-intestinal involvement. The asso-
ciation of microbiota with Behçet syndrome has not been shown yet. Our work was aimed to compare the gut
microbiota structure and the profiles of short-chain fatty acids production in Behçet syndrome patients and
healthy control relatives.
Methods:Here, we compared the fecalmicrobiota of 22 patientswith Behçet syndrome and that of 16 healthy co-
habiting controls, sharing the same diet and lifestyle by pyrosequencing of the V3–V4 hypervariable regions of
the 16 rDNA gene and biochemical analyses.
Results: Our analyses showed significant differences in gut microbiota between Behçet patients and healthy co-
habitants. In particular we found that Behçet's patients were significantly depleted in the genera Roseburia and
Subdoligranulum. Roseburia showed a relative abundance value of 10.45 ± 6.01% in healthy relatives and
4.97 ± 5.09% in Behçet's patients, and Subdoligranulum, which reached a relative abundance of 3.28 ± 2.20% in
healthy controls, was only at 1.93 ± 1.75% of abundance in Behçet's patients. Here we report, for the first time,
that a peculiar dysbiosis of the gut microbiota is present in patients with Behçet syndrome and this corresponds
to specific changes inmicrobiome profile. A significant decrease of butyrate production (P=0.0033) in Behçet's
patients was demonstrated. Butyrate is able to promote differentiation of T-regulatory cells, and consequently
the results obtained prompt us to speculate that a defect of butyrate production might lead to both reduced T-
reg responses and activation of immuno-pathological T-effector responses.
Conclusions: Altogether, our results indicate that both a peculiar dysbiosis of the gut microbiota and a significant
decrease of butyrate production are present in patients with Behçet syndrome.Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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41. Introduction
Behçet syndrome (BS) is a systemic vasculitis characterized by
muco-cutaneous and ocular manifestations, with central nervous sys-
tem, vascular and gastro-intestinal involvement [1,2]. BS is common in
the Middle East, Mediterranean countries, Asia, and Japan, whereas it
is quite rare in the United States and Northern European countries [3,
4]. To date diagnosis is only based on clinical criteria as no sensitive
and specific relevant biological tests are available [5,6]. It has been re-
ported that carrying the human leukocyte antigen (HLA)-B51 increases
the risk of developing BS by 1.5 to 16 times [7–9]; however, except for
the severity of ocular disease [10], HLA-B51 does not seem to be corre-
lated with the prognosis of BS. The exact cause of BS remains unknown
but it is believed that both genetic and environmental factors contribute
to the development of the disease [11,12], by the interaction between
genetic background and infectious agents that might concur to the im-
mune dysregulation [13–16]. A role of oral flora has also been consid-
ered in the etiopathogenesis of BS given the high frequency of oral
ulcers [4]. The activation of innate immune responses by pathogens,
and the consequent interaction between activated T-cells with neutro-
phils, can determine tissue damage and vasculitis in BS [17,18].
The human gutmicrobiota (GM) – the enormous community of sym-
biont microorganisms inhabiting our gut – has been recognized as a key
factor for human health and homeostasis [19,20]. The role of GM in our
physiology is so profound that human beings have been reconsidered
as super-organisms, as a result ofmillennia of co-evolutionwith theirmi-
crobial counterpart [21]. Even if the main evolutionary force shaping the
GM–host mutualism has been the microbiome-dependent increase of
energy extraction from food [22,23], the recent adoption of germ-free
mouse models allowed to disclose several aspects of the human biology
which rely on the mutualistic interaction with our “microbial organ,”
such as the energetic homeostasis [24], the estrogen equilibrium [25]
and the function of the immune system [26]. In particular, GM is an active
component of our immune system, being essential for immune educa-
tion during the early life and for themaintenance of the immune homeo-
stasis during the entire life course [27,28]. Short chain fatty acids (SCFAs)
– butyrate, propionate and acetate – are the downstream mediators of
the GM anti-inflammatory activity, showing a pivotal role in the immu-
nological cross-talk with the host [29]. The concerted action of these
three metabolites is the endpoint of GM community fermentation pro-
cesses in the gut and is fundamental to preserve immune homeostasis
and functionality of the host immune system [30]. In particular, it has
been shown inmice that GM is able to dictate the type of T-cell responses
elicited in the host [31,32]. Current evidence indicates that GM is impor-
tant in health and diseases, including gastroenterologic, autoimmune,
and even neuropsychiatric disorders [33–35].
While amutualistic SCFA-producing GM configuration is a key factor
to preserve thehumanhealth, GMdysbioses toward a pro-inflammatory
layout have been implicated in the onset, progression and consolidationof several immune disorders, such as inflammatory bowel disease (IBD),
colorectal cancer, type II diabetes and allergy [20,27,36]. It has been also
hypothesized that an impairedmicrobiome–host interactionmight con-
tribute to the genesis of BS [37].
The aim of this study was to compare the GM structure and the pro-
files of SCFA production in BS patients and healthy control relatives eat-
ing the same diet and living in the same environment of BS patients.
Here, we report that a peculiar dysbiosis of the gutmicrobial ecosystem
is present in patients with BS, corresponding to specific changes in the
profiles of SCFA production; in particular a significant decrease of buty-
rate production in Behçet's patients was demonstrated. Interestingly
butyrate is able to induce T regulatory cell (Treg) differentiation via sev-
eral mechanisms, thus influencing immune regulation [38] probably
promoting an abnormal immune system response.
Altogether, the results obtained in this study lead us to speculate
that novel diet- and/or probiotic-based strategies specifically tailored
to the manipulation of the intestinal dysbiosis in BS might be useful
for both prevention and treatment of the disease.
2. Methods
2.1. Subject enrolment and sample collection
In the present study 38 subjects were enrolled, including 22 patients
with BS (12 males and 10 females; mean age, 41.1 years) attending the
Florence Behçet Center and 16 age-matched healthy controls (6 males
and 10 females; mean age 43.4 years). All participants had a comparable
lifestyle in the last 6 months, in particular the same Mediterranean diet,
without assumption of probiotics or antibiotics. Healthy controls of the
study lived in the same house of BS patients: in 5 cases the control was
a first-degree relative, while in the other 11 a cohabitant. Participants
who had other diseases, such as autoimmune disorders, infections orma-
lignancies, that might affect the outcome were excluded from the study.
All the patients were diagnosed as BS according to ISGC, the mean
duration of illness was between 11 months and 27 years and 50% of
them showed a HLA-B51 serotype. Oral aphthosis was present in all pa-
tients, followed by genital ulcers (63.5%), articular involvement (50%),
cutaneous manifestations (35%), intestinal symptoms with or without
endoscopic lesions (32%), vascular involvement (30%) and ocular im-
pairment (29%); only 13% of patients presented central nervous system
involvement (Fig. S1). Pathergy test was positive in 5 of 22 patients.
The study protocol was approved by the Ethical Committee of
Azienda Ospedaliero-Universitaria (AOU) Careggi, Florence, Italy. In-
formed consent was obtained from all subjects.
2.2. Microbial DNA extraction from feces
Total bacterial DNA from fecal material was extracted using the
QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA, USA) with a
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1 ml of lysis buffer (500 mM NaCl, 50 mM Tris–HCl pH 8, 50 mM
EDTA, 4% SDS) and 3 times bead-beaten with four 3-mm glass
beads and 0.5 g of 0.1-mm zirconia beads (BioSpec Products, Bartles-
ville, OK, USA) in a FastPrep-24 Instrument (MP Biomedicals, Santa
Ana, CA, USA) at 5.5 m/s for 1 min. After incubation at 95 °C for
15 min and centrifugation at full speed for 5 min to pellet stool par-
ticles, 260 μl of 10 M ammonium acetate was added to the superna-
tant, followed by incubation in ice for 5 min and centrifugation for
10min. One volume of isopropanol was added to each sample and in-
cubated in ice for 30 min. Precipitated nucleic acids were washed
with 70% ethanol, resuspended in 100 μl of TE buffer and treated
with 2 μl of DNase-free RNase (10 mg/ml) at 37 °C for 15 min. Each
DNA sample was further treated with Proteinase K and purified
with QIAamp Mini Spin columns (QIAGEN) following the
manufacturer's instructions. DNA concentration and quality for
each sample were determined using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA).
2.3. 16S rRNA gene amplification
For the amplification of the V4 region of the 16S rRNA gene the
primer set 520F (5′-AYTGGGYDTAAAGNG-3′) and 802R (5′-TACNV
GGGTATCTAATCC-3′) (with Y = C/T, D = A/G/T, N = any base, V =
A/C/G) [40] was utilized. Primers included at their 5′ end an adaptor se-
quence used in the 454-sequencing library preparation protocol, linked
to a unique MID tag barcode of 10 bases that allowed the identification
of the different samples. Amplifications were carried out in 50-μl final
volume reaction mixtures containing 0.5 μM of each forward and re-
verse primer, together with 100 ng of template DNA, 2.5 U of GoTaq
Flexi Polymerase (Promega, Madison, WI, USA), 200 μM of dNTPs and
2 mM of MgCl2. Samples were initially denatured at 95 °C for 5 min,
followed by 35 cycles of 94 °C for 50 s, 40 °C for 30 s, and 72 °C
for 60 s, with a final extension step at 72 °C for 5 min [41]. PCR amplifi-
cations were performed in a Biometra Thermal Cycler T Gradient
(Biometra, Goettingen, Germany).
2.4. Pyrosequencing
16S rRNA geneV4 hypervariable region ampliconswere individually
purifiedwithMinElute PCR Purification Kit (QIAGEN) and, then, quanti-
fied using the Quant-iT PicoGreen dsDNA kit (Invitrogen, Carlsbad, CA,
USA). After the individual quantification step, amplicons were pooled
in equal amounts (creating four 6-plex and two 7-plex pools) and
again purified by 454-Roche Double Ampure size selection protocol
with Agencourt AMPure XP DNA purification beads (Beckman Coulter
Genomics GmbH, Danvers, MA, USA) in order to remove primer dimers,
according to the manufacturer's instructions (454 LifeSciences, Roche,
Branford, CT, USA). Before emulsion PCR, purified amplicon pools
were quantified using a quantitative Real Time PCR (qPCR) by KAPA Li-
brary Quant Kits (KAPA Biosystems,Wilmington,MA, USA). Afterwards,
pools were fixed to microbeads to be clonally amplified by emulsion
PCR following the GS-FLX protocol Titanium emPCR LIB-A (454
LifeSciences, Roche). Following this amplification step, beads were
enriched in order to keep only those carrying identical PCR products
on their surface, and loaded onto a picotiter plate for pyrosequencing re-
actions, following the GS-FLX Titanium sequencing protocol. Each pool
was sequenced in one eighth of a plate.
2.5. SCFA analysis
For the extraction of SCFAs the method described in Schnorr et al.
[41] was followed. Briefly, 250 mg of fecal samples were extracted by
adding 1 ml of 10% perchloric acid in water and centrifuged at
15,000 g for 5 min at 4 °C. Fifty microlitres of supernatant were diluted
1:10 in water, 10 μl of D8-butyric acid (internal standard, IS) wereadded to the sample at the final concentration of 20 μg/ml. The sample
was stirred for 10min at 70 °C to reach the equilibrium of volatile com-
pounds between the matrix and the headspace. Then, SCFA extraction
was performed by using a 75-μm Carboxen/polydimethylsiloxane fiber
(Supelco, Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 70 °C. After
extraction, samples were directly desorbed into the gas chromatograph
(GC) injection port at 250 °C for 10 min, including fiber cleaning. The
GC–mass spectrometry (GC–MS) analysis was performed on a TRACE
GC 2000 Series (ThermoQuest CE Instruments, Waltham, MA, USA),
interfaced with GCQ Plus (ThermoQuest CE Instruments) mass detector
with ion trap analyzer, operating in EI mode (70 eV). The GC was oper-
ated in splitless mode; the injector base temperature was set at 250 °C.
The capillary GC columnwas a Phenomenex ZB-WAX (30m× 0.25mm
ID, 0.15 μm film thickness), consisting of 100% polyethylene glycol.
Helium (He) was the carrier gas at a flow rate of 1.0 ml/min. An oven
temperature program was adopted: initial 40 °C (hold time: 5 min),
and then ramped by 10 °C/min to 220 °C (hold time: 5 min). The tem-
perature of transfer line and ionization source was maintained at
250 °C and 200 °C, respectively. The mass spectra were recorded in
full scanmode (34–200 a.m.u.) to collect the total ion current chromato-
grams. The compoundswere identified by comparison of retention time
andmass spectra with those of commercial reference standards provid-
ed by Sigma-Aldrich. Quantification was carried out by using the ex-
tracted ion chromatograms by selecting fragment ions of the studied
analytes (43 and 60 a.m.u. for acetic acid, 55 and 73 a.m.u. for propionic
acid, 60 and 73 a.m.u. for butyric and valeric acids, and 63 and 77 a.m.u.
for IS). The SCFA concentration in fecal sampleswas expressed in μmol/g
of feces. Limit of detection ranged from 4 to 68 nmol/g.
All the standards (purity N99%), acetic, propionic, butyric, valeric
acids and IS were provided by Sigma-Aldrich and were used to prepare
calibration solutions for quantification (linear response). The calibra-
tion curves were prepared by adding the IS to scalar amounts of the
acids in water or diluted samples (for external standardization and
recovery).2.6. Bioinformatic analysis and statistical data analysis
Sequencing reads were analyzed using the QIIME pipeline [42] as
described previously [41]. Briefly, pyrosequencing V4 reads were fil-
tered according to the following criteria: (i) read length between
150 bp and 350 bp; (ii) no ambiguous bases (Ns) in the reads; (iii) a
minimum average quality score of 25 over a 50-bp rolling window;
(iv) exact match to primer sequences and maximum 1 error in barcode
tags. Trimmed reads were clustered into OTUs at 97% identity level,
aligned against the Greengenes database [43] by PyNAST algorithm
and filtered for chimeric sequences using ChimeraSlayer (http://
microbiomeutil.sourceforge.net/#A_CS). RDP-classifier (version 2.2)
with 50% confidence value threshold was used for bacterial taxonomy
assignment. Alpha-diversity and rarefaction plots were computed
using Shannon, PDwhole tree, chao1 and observed speciesmetrics. Sta-
tistical evaluation of differences in alpha-diversity indices was per-
formed by a non parametric, Monte Carlo-based test, using 9999
random permutations. Principal coordinates analysis (PCoA) was per-
formed using both weighted and unweighted UniFrac distances, and
data separation was tested using a permutation test with pseudo F-
ratios (adonis test with pseudo F-ratios on 9999 permutations). Hierar-
chical clustering using Spearman rank correlation distance and average
linkage, and heatmaps were performed on relative abundance (rel. ab.)
values at family level in TMeV 4.6.2 [44]. Statistical analysis of GM dif-
ferences between BS patients and controls was performed in Matlab
(MathWorks, Natick, MA. USA), using a Wilcoxon signed rank test.
The Kendall correlation test between SCFA levels and the relative abun-
dance of genera was achieved using function “cor.test” of the package
“Stats” of R. In all statistical tests, a p-value b 0.05 was considered as
significant.
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3.1. Intestinal microbiota in Behçet's patients
GM structure from 22 Behçet's patients and 16 healthy relatives, be-
longing to 21 different families (Table S1),was characterized bymean of
pyrosequencing of the V4 region of the bacterial 16S rRNA gene
(Fig. S2a,b,c). A total of 261,958 high-quality reads were obtained,
with a mean of 6,893 ± 2,673 reads (range 2760–12,581) per subject.
Reads were clustered in 7652 operational taxonomic units (OTUs) at
97% of identity. OTU rarefaction curves based on number of unique
OTUs, Shannon, Chao1 and phylogenetic diversity metrics reached the
plateau after about 2500 reads (Fig. S3), suggesting that the depth of
coverage we accomplished was sufficient to capture nearly the entire
biological diversity within samples.
The GM of both BS patients and healthy controls was largely domi-
nated by Firmicutes (relative abundance (rel. ab.) 86.0 ± 10.9% and
88.4 ± 6.8%, respectively), Actinobacteria (rel. ab. 5.9 ± 9.3% and
5.8 ± 6.5%, respectively) and Bacteroidetes (rel. ab. 6.8 ± 5.0% and
5.1 ± 3.8%, respectively).
The most represented families in gut microbial communities were
Ruminococcaceae (rel. ab. 31.9 ± 11.9% and 34.9 ± 9.3% in BS and con-
trols, respectively), Lachnospiraceae (rel. ab. 21.9 ± 9.8% and 25.1 ±Fig. 1. α-Diversity rarefaction curves for the 16S rRNA V4 region pyrosequencing reads. A
(PD_whole_tree, A), observed species (B), Chao1 (C) and Shannon diversity (D) are reported
the number of sequences per sample used for the calculation. Curves were built calculating the
between 27 to 2700 sequencing reads.7.0%, respectively), Clostridiales (rel. ab. 10.5 ± 5.9% and 7.1 ± 3.0%, re-
spectively), Clostridiales Incertae Sedis XIV (rel. ab. 13.3 ± 9.5% and
12.6 ± 5.8%, respectively), Bifidobacteriaceae (rel. ab. 5.7 ± 9.2% and
5.6 ± 6.5%, respectively) and Bacteroidaceae (rel. ab. 4.2 ± 4.6% and
2.2 ± 1.3%, respectively). Subdominant families showing rel. ab. values
below 5% were: Erysipelotrichaceae, Eubacteriaceae, Rikenellaceae,
Porphyromonadaceae, and Enterobacteriaceae (Fig. S2b).
3.2. Comparison between GM communities in Behçet's patients and healthy
relatives
In order to highlight GM dysbiosis signatures of BS, a detailed com-
parative analysis of the GM communities in Behçet's patients and
healthy relatives was performed. At first, we sought the degree of
intrasubject GM diversity in the two groups. Interestingly, comparison
of rarefaction curves indicated a reduced diversity for the gut microbial
community in BS (Fig. 1). Confirming this observation, community rich-
ness comparison by using different metrics – Shannon diversity, Chao1,
observed species and PDwhole tree– always showed a significantly (P b
0.01) lower degree of α-diversity in the BS gut microbial ecosystem re-
spect to healthy controls (Table S2). To investigate the degree of
intersubject GMdiversity (β-diversity) in our study cohort, we calculat-
ed unweighted and weighted UniFrac phylogenetic distances of the GMverage indexes (plus standard error bars) for the phylogenetic diversity whole tree
for the Behçet (red line, n = 22) and control (blue line, n = 16) groups. X-axis reports
average diversity index on 10 random extractions for 100 linearly spaced sampling points
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sentation of both unweighted and weighted UniFrac distances resulted
in the separation of Behçet's patients and healthy controls (Fig. 2), with
significant values obtained with unweighted UniFrac distance metrics
(P= 0.0114), suggesting that the differences between the two subject
groups likely involved a subdominant fraction of the GM. Average β-di-
versity indexes among the samples coming from Behçet or control
group indicated no difference but comparable levels of β-diversity be-
tween the two study groups (average β-diversity for unweighted
UniFrac distances: 0.68 ± 0.16 in Behçet's patients and 0.65 ± 0.17 in
controls; average β-diversity for weighted UniFrac distances: 0.59 ±
0.17 in Behçet's patients and 0.52 ± 0.18 in controls).
In Table 1 we report phylum- to genus-level differences between
GM from Behçet's patients and healthy relatives. While no significant
difference at the level of phylumwas found, Behçet's patients were sig-
nificantly depleted in the dominant GM genera Roseburia and
Subdoligranulum, which belong to the Clostridium clusters XIVa and IV,
respectively. In particular, Roseburia showed a rel. ab. value of 10.45 ±
6.01% in healthy relatives and 4.97 ± 5.09% in Behçet's patients, and
Subdoligranulum, which reached a rel. ab. of 3.28 ± 2.20% in healthy
controls, was only at 1.93± 1.75% of abundance in Behçet's patients. In-
terestingly, the unsupervised hierarchical clustering at family level did
not show sample separation either according to BS status or degree of
kinship (Fig. S4), suggesting that the GM dysbioses associated to BS
overcame intrinsic GM similarities among individuals of the same fam-
ily, although differences were not enough to show a clear separation ac-
cording to disease state of the samples.
3.3. SCFA profiles
The abundance of SCFAs in stool samples from Behçet's patients and
healthy relativeswas determined by GC–MS (Table S3). The PCoA of the
individual SCFA profiles showed a significant (P= 0.0339) segregation
between Behçet's patients and healthy relatives (Fig. 3). In particular,
Behçet's patients were characterized by a significant reduction of buty-
rate (P = 0.0033) and a tendency toward a corresponding increase in
acetate (P= 0.068) (Fig. S5). No difference, on the other side, was ob-
served for propionate.
In order to dissectwhether themajor dysbioses of theGMstructure of
Behçet's patients could have an impact on their peculiar profile of SCFAs,
Kendall correlation values between Roseburia and Subdoligranulum –
both significantly reduced in Behçet's patients – and acetate, propionate
and butyrate were calculated. Interestingly, Roseburia showed aFig. 2.Differences inGMstructure between Behçet's patients and healthy relatives. PCoA of thew
Behçet (red squares) or control (blue circles) group. Percent variance accounted for by the firstendency (P = 0.073) toward a positive association with butyrate
(Kendall correlation=0.207). Differently, Subdoligranulumdidnot result
in any correlation with SCFAs.
4. Discussion
Based on the hypothesis that GM structure and function could affect
the pathogenesis of BS, here we sought GM dysbioses in BS and the cor-
respondingoutcome in termsofmicrobiota–host trans-genomicmetab-
olism. By comparingGM structure and SCFA content in Behçet's patients
and healthy controls, we have successfully described peculiar distor-
tions of the GM profile in BS, as well as the consequent impact in
terms of pattern of SCFA production. In particular, the BS-associated
GMwas characterized by a significant reduction of the total bacterial di-
versity compared to a healthy intestinal ecosystem. Furthermore, a sig-
nificant depletion of Roseburia and Subdoligranulum in the GM of
Behçet's patients was observed. Belonging to the Clostridium clusters
XIVa and IV, respectively, these microorganisms are well-known buty-
rate producers of the human GM and are generally associated with a
healthy GM structure [45,46]. Strengthening these findings, we demon-
strated a significant decrease of butyrate production in Behçet's
patients.
Taken together, our data provide experimental evidence supporting
a dysbiotic structure of the GM ecosystem in BS; characterized by a low
biodiversity and by a depletion of key butyrate-producingmembers, the
GM of Behçet's patients deviates from a mutualistic layout, resulting in
an overall decrease of butyrate abundance in the gut. Butyrate is a key
microbial metabolite in the context of the GM–host mutualism, with a
well-consolidated role as a modulator of the host immune function. In
particular, butyrate exerts an important role for the maintenance of
the host immune homeostasis [30], showing both systemic and local
immuno-modulating properties. In fact, while circulating butyrate
prompts the generation of extrathymic Treg [47], gut butyrate has
been reported to inhibit local pro-inflammatory cytokines [48]. The
role of butyrate in host physiology goes beyond the immune function.
In fact, butyrate represents the main energy source for colonocytes
[49] and, stimulating the release of mucins, it also exerts a protective
role strengthening the gut epithelial barrier [50].
T-lymphocytes producing interferon-γ and interleukin 17, together
with neutrophils, are thought to represent the main effector cells in
the pathogenesis of BS [37]. Interestingly, butyrate is able to promote
differentiation of Treg via several mechanisms, thus influencing im-
mune regulation and altering the mucosal immune response [38]; theeighted (A) and unweighted (B)UniFrac distances, represented according to belonging to
t and second principal component (PC) is shown.
Table 1
List of taxonomic units enriched or depleted in the GM of Behçet's patients with respect to healthy relative controls. For each taxonomical group, the average relative abundance (plus
standard deviation) and the P-value of the Mann–Whitney U-test between the two groups are reported. Only P-values b 0.3 are shown. .
Phylogenetic level Taxonomy Behçet Avg rel. ab.
(st. dev)
Controls Avg rel. ab.
(st. dev)
P-valuea
Phylum Bacteria; Lentisphaerae 0.00 (0.01) 0.00 (0.00) 0.236
Bacteria; TM7 0.00 (0.01) 0.00 (0.00) 0.236
Bacteria; Bacteroidetes 6.80 (5.04) 5.11 (3.84) 0.268
Class Bacteria; Firmicutes; Bacilli 0.62 (0.65) 0.46 (0.74) 0.084
Bacteria; Bacteroidetes; Sphingobacteria 0.01 (0.02) 0.00 (0.00) 0.137
Bacteria; Lentisphaerae; Lentisphaeria 0.00 (0.01) 0.00 (0.00) 0.236
Order Bacteria; Actinobacteria; Actinobacteria; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Proteobacteria; Deltaproteobacteria; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Firmicutes; Clostridia; Other 0.43 (1.53) 0.05 (0.10) 0.065
Bacteria; Firmicutes; Bacilli; Lactobacillales 0.62 (0.65) 0.45 (0.74) 0.074
Family Bacteria; Actinobacteria; Actinobacteria; Other; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Proteobacteria; Deltaproteobacteria; Other; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Firmicutes; Clostridia; Clostridiales; Other 10.49 (5.87) 7.10 (2.97) 0.043⁎
Bacteria; Firmicutes; Clostridia; Other; Other 0.43 (1.53) 0.05 (0.10) 0.065
Bacteria; Bacteroidetes; Bacteroidia; Bacteroidales; Other 0.32 (1.27) 0.03 (0.06) 0.073
Genus Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Roseburia 4.97 (5.09) 10.45 (6.01) 0.004⁎⁎
Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Papillibacter 0.73 (1.02) 0.24 (0.39) 0.040⁎
Bacteria; Actinobacteria; Actinobacteria; Coriobacteriales; Coriobacteriaceae; Asaccharobacter 0.01 (0.02) 0.02 (0.03) 0.040⁎
Bacteria; Actinobacteria; Actinobacteria; Other; Other; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Proteobacteria; Deltaproteobacteria; Other; Other; Other 0.00 (0.00) 0.01 (0.02) 0.040⁎
Bacteria; Firmicutes; Clostridia; Clostridiales; Other; Other 10.49 (5.87) 7.1 (2.97) 0.043⁎
Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Subdoligranulum 1.93 (1.75) 3.28 (2.20) 0.049⁎
Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Lactonifactor 1.24 (1.32) 0.59 (0.59) 0.053
Bacteria; Firmicutes; Clostridia; Other; Other; Other 0.43 (1.53) 0.05 (0.10) 0.065
Bacteria; Actinobacteria; Actinobacteria; Coriobacteriales; Coriobacteriaceae; Slackia 0.00 (0.00) 0.01 (0.01) 0.066
Bacteria; Bacteroidetes; Bacteroidia; Bacteroidales; Other; Other 0.32 (1.27) 0.03 (0.06) 0.073
Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Robinsoniella 0.14 (0.32) 0.05 (0.09) 0.074
a Mann–Whitney U-test.
⁎ P b 0.05.
⁎⁎ P b 0.01.
274 C. Consolandi et al. / Autoimmunity Reviews 14 (2015) 269–276butyrate impairment in BS patients could favor a reduced Treg-
mediated control, thus promoting a powerful immuno-pathological T-
cell responses. In our cohort of Behçet's patients the presence of HLA-
B51 does not seem to be correlated to a specific GM profile.
Interestingly, GM dysbioses similar to the ones we detected in
Behçet's patients have been previously observed in IBD, whose patients
are generally characterized by a reduction of GM ecosystem diversity,
the decrease of butyrate producers belonging to the Clostridium clusters
IV and XIVa, and the corresponding decrease of butyrate production in
the gut [29,51]. These deviations from a GMmutualistic structure haveFig. 3. Comparison of SCFA production between Behçet's patients and healthy relatives.
PCoA based on Euclidean distances of the profiles of SCFA relative abundance in Behçet's
patients (B, red dots) and healthy control relatives (C, blue dots). Percentage of variance
explained by the first and second PC is reported.been hypothesized to contribute to IBD onset and progression through
the establishment of a self-sustained pro-inflammatory loop in the gut
[52].
Providing evidence of characteristic GM deviations from a healthy
profile in BS, our data open the perspective to a therapeutic manipula-
tion of GM structure in Behçet's patients, specifically targeted to the re-
covery of a mutualistic layout. For instance, besides the usage of
probiotics, the content of dietary fiber can be specifically modulated in
order to favor the increase of butyrate producers in the gut. Accordingly
it has been recently demonstrated that oral administration of butyrate
inmice is able to both favor Treg differentiation and to ameliorate colitis
[30,53].
Supporting the recovery of a healthy pattern of SCFA production,
these microorganisms could promote the immune homeostasis in BS,
thus allowing the control of disease.
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Take home messages
• BS is a vasculitis with muco-cutaneous, ocular, and gastro-intestinal
involvement.
• BS is associated to a peculiar dysbiosis of the gut microbial ecosystem.
• Gutmicrobiota ecosystem in BS is characterized by a low biodiversity.
• Behçet's patients were significantly depleted in the genera Roseburia
and Subdoligranulum.
• BS patients show a decrease of butyrate production.
• The defect of butyrate production leads to reduced T-reg responses
and activation of immuno-pathological T-effector responses.
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